ImmvaRx

ImmvaRx is a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies through its proprietary ProtEx™ platform technology. This platform enables the rapid and stable display of bioactive immunological ligands on the surface of tumor cells or microvesicles, effectively transforming them into potent therapeutic vaccines. By engineering the immune system to recognize and attack tumors via the localized delivery of costimulatory molecules like 4-1BBL and OX40L, ImmvaRx aims to overcome the immunosuppressive tumor microenvironment. The company's lead candidate, IRX-201, is designed to stimulate a robust T-cell response against advanced solid tumors. ImmvaRx's approach is intended to be used both as a monotherapy and in combination with existing checkpoint inhibitors to improve patient outcomes in oncology.